Company Overview
Company Type: Public Company
Website: nymox.com
Number of Employees: 16
Ticker: NYMX.F (OTCPK)
Year Founded: 1989


Business Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer’s disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
57.9
EBITDA
(3.3)
Total Enterprise Value
58.8
TEV/EBITDA
NM
EBIT
(3.1)
Cash & ST Invst.
0.2
P/Diluted EPS Before Extra
NM
Net Income
(7.2)
Total Debt
1.1
Price/Tang BV
NM
Capital Expenditure
0.0
Total Assets
0.4
Total Debt/EBITDA
NM




Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-10-2023

Key Professionals
Name
Title
Averback, Paul 
Founder, Chairman, CEO & President
Dodd, Lin 
QA and Compliance Manager
Doody, Patrick 
VP, General Counsel & Director

Key Board Members
Name
Title
Averback, Paul 
Founder, Chairman, CEO & President
Doody, Patrick 
VP, General Counsel & Director
Robinson, James G.
Independent Director
Morse, David S.
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
Bay & Deveaux Streets | Nassau | Bahamas
Phone: 800 936 9669   Fax: 514 332 2227

Current and Pending Investors
Wedbush Securities Inc.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.68
Market Cap (mm)
62.1
Open
 0.68
Shares Out. (mm)
91.3
Previous Close
 0.68
Float %
55.7%
Change on Day
0.05
Shares Sold Short (mm)
0.1
Change % on Day
7.3%
Dividend Yield %
-
Day High/Low
 0.69/ 0.68
Diluted EPS Excl. Extra Items
(0.09)
52 wk High/Low
 1.56/ 0.16
P/Diluted EPS Before Extra
NM
Volume (mm)
0.02
Avg 3M Dly Vlm (mm)
0.09
Beta 5Y
1.18


 
Delayed Quote** | Last Updated on Oct-11-2023 12:00 AM (GMT-5)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Serex, Inc.
Serex, Inc. manufactures and markets diagnostic equipment. The company offers Serex LabTab system used for testing blood, urine and saliva and NicoMeter, which measure tobacco use or exposure in the body by testing urine and saliva. Serex was founded in 1983 and is based in Maywood, New Jersey. As of 03/02/2000, Serex, Inc. is a subsidiary of Nymox Pharmaceutical Corp.

United States and Canada
Health Care Equipment
-
-
-
Nymox Corporation

United States and Canada
-
3.00
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-02-2023
Aug-29-2023
Private Placement
Target
Nymox Pharmaceutical Corporation (OTCPK:NYMX.F)


2.00
Mar-28-2022
-
Shelf Registration
Target
Nymox Pharmaceutical Corporation (OTCPK:NYMX.F)


4.65
Mar-18-2022
Mar-22-2022
Public Offering
Target
Nymox Pharmaceutical Corporation (OTCPK:NYMX.F)


6.40
Dec-9-2021
-
Shelf Registration
Target
Nymox Pharmaceutical Corporation (OTCPK:NYMX.F)


25.00
May-11-2021
-
Shelf Registration
Target
Nymox Pharmaceutical Corporation (OTCPK:NYMX.F)


6.46
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-25-2023
Product-Related Announcements
Nymox Pharmaceutical Corporation Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH
Sep-07-2023
Delistings
The Nasdaq Stock Market to Delist the Common Stock of Nymox Pharmaceutical
Aug-29-2023
Private Placements
Nymox Pharmaceutical Corporation announced that it has received $2 million in funding
Aug-02-2023
Private Placements
Nymox Pharmaceutical Corporation announced that it expects to receive $2 million in funding
Jul-25-2023
Product-Related Announcements
Nymox Pharmaceutical Corporation Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results

Competitors
Abbott Laboratories (NYSE:ABT), Abraxis LLC, CareFusion Corporation, Gfc Diagnostics Limited, Laboratory Corporation of America Holdings (NYSE:LH), Mossman & Associates Limited, OraSure Technologies, Inc. (NasdaqGS:OSUR), Quest Diagnostics Incorporated (NYSE:DGX), Roche Diagnostics Corporation, Roche Holding AG (SWX:ROG), Siemens Medical Solutions Diagnostics, Inc.


Advisors
Most Recent Auditor
TPS Thayer, LLC
Private Placement Advisors
Alliance Global Partners, Cantone Asset Management, LLC, Ladenburg Thalmann & Co. Inc.
Public Offering Advisors
Alliance Global Partners, Cutler Law Group, KPMG LLP, Thayer O'Neal Company, LLC, TPS Thayer, LLC, Zouvas & Associates, LLP


Most Recent Auditor
TPS Thayer, LLC


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

06:04 AM
NYMX.F
Nymox Pharmaceutical Corp (NYMXF.OTC) - Medical Equipment - Deals and Alliances Profile
Reports
71
The Economy Matters

Oct 09, 2023 01:42 AM
NYMX.F
The Economy Matters
Reports
8
S&P Global Compustat

Oct 05, 2023 03:23 AM
NYMX.F
Nymox Pharmaceutical Corp 2023_10_05
Reports
14
GlobalData

Oct 05, 2023 01:47 AM
NYMX.F
Nymox Pharmaceutical Corp (NYMXF.OTC) - Financial and Strategic SWOT Analysis Review
Reports
198
GlobalData

Sep 21, 2023 05:46 AM
NYMX.F
Nymox Pharmaceutical Corp (NYMXF.OTC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
83
GlobalData

Sep 19, 2023 05:16 AM
NYMX.F
Nymox Pharmaceutical Corp (NYMXF.OTC) - Financial and Strategic SWOT Analysis Review
Reports
197
GlobalData

Sep 15, 2023 04:17 AM
NYMX.F
Nymox Pharmaceutical Corp (NYMXF.OTC) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
131
GlobalData

Sep 12, 2023 06:42 AM
NYMX.F
Nymox Pharmaceutical Corp (NYMXF.OTC) - Medical Equipment - Deals and Alliances Profile
Reports
71
S&P Global Compustat

Sep 07, 2023 03:10 AM
NYMX.F
Nymox Pharmaceutical Corp 2023_09_07
Reports
14
Jefferson Research & Management

Jul 07, 2023 02:46 PM
NYMX.F
Jefferson Financial - Nymox Pharmaceutical Corporation
Reports
11


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Averback DABP, M.D., Paul 

33,508,010

36.72

24.1

Apr-19-2023


Robinson, James G.

4,782,065

5.24

3.4

Apr-27-2023


Danielsen, Erik 

1,182,500

1.30

0.9

Mar-30-2022


Lanham Esq., J.D., Randall J.

925,000

1.01

0.7

Apr-19-2023


Corrigan Financial Inc

302,252

0.33

0.2

Jun-30-2023


Cetera Financial Holdings, Inc., Asset Management Arm

118,900

0.13

0.1

Jun-30-2023


Morgan Stanley, Investment Banking and Brokerage Investments

98,686

0.11

0.1

Jun-30-2023


Simplicity Solutions, LLC

80,000

0.09

0.1

Jun-30-2023


Bleakley Financial Group, LLC

80,000

0.09

0.1

Jun-30-2023


D.F. Dent and Company, Inc.

75,000

0.08

0.1

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Lanham Esq., J.D., Randall J.
925,000
472,100
Robinson, James G.
4,782,065
80,000
D.F. Dent and Company, Inc.
75,000
75,000
UBS Asset Management AG
34,530
34,155
Lincoln Financial Investments Corporation
11,215
11,215

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Averback DABP, M.D., Paul 
33,508,010
(6,525,000)
BlackRock, Inc.
38,689
(96,923)
Millennium Management LLC
0
(47,916)
Citadel Advisors LLC
25,040
(35,266)
Two Sigma Securities, LLC, Asset Management Arm
11,737
(9,585)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
AlzheimAlert, Donepezil HCI, Fexapotide (Future), Fexapotide Triflutate (Future), Galantamine Hydrobromide, Memantine, NicAlert, NX02-0017 (Future), NX02-0018 (Future), NXB-4221, NXB-5886, NXC-4720 (Future), NXD-1191 (Future), NXD-3109 (Future), NXD-5150 (Future), NXT-1021, NYMOZARFEX (Future), Rivastigmine, Tacrine, TobacAlert


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Reporting Owner(s)
Source
Form Type
Size
Sep-25-2023
Sep-25-2023
Nymox Pharmaceutical Corporation (OTCPK:NYMX.F)

SEC
6-K
25 KB
Sep-08-2023
-
Nymox Pharmaceutical Corporation (OTCPK:NYMX.F)
The NASDAQ Stock Market LLC
SEC
25-NSE
4 KB
Aug-29-2023
Aug-29-2023
Nymox Pharmaceutical Corporation (OTCPK:NYMX.F)

SEC
6-K
27 KB
Aug-14-2023
Jun-30-2023
Nymox Pharmaceutical Corporation (OTCPK:NYMX.F)

SEDAR
Interim Financial Statements
131 KB
Aug-14-2023
Jun-30-2023
Nymox Pharmaceutical Corporation (OTCPK:NYMX.F)

SEC
6-K
2 MB
Aug-02-2023
Aug-02-2023
Nymox Pharmaceutical Corporation (OTCPK:NYMX.F)

SEC
6-K
25 KB
Jul-31-2023
Jul-31-2023
Nymox Pharmaceutical Corporation (OTCPK:NYMX.F)

SEC
6-K
1 MB
Jul-25-2023
Jul-25-2023
Nymox Pharmaceutical Corporation (OTCPK:NYMX.F)

SEC
6-K
1 MB
Jul-25-2023
Jul-25-2023
Nymox Pharmaceutical Corporation (OTCPK:NYMX.F)

SEC
6-K
1 MB
Jul-12-2023
Jul-12-2023
Nymox Pharmaceutical Corporation (OTCPK:NYMX.F)

SEC
6-K
30 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Robinson, James G. (Independent Director)
Apr-27-2023
Common Shares
40,000
25,570
Open Market Acquisition
0.84
Form 4
Robinson, James G. (Independent Director)
Apr-25-2023
Common Shares
40,000
24,482
Open Market Acquisition
0.85
Form 4
Robinson, James G. (Independent Director)
May-02-2022
Common Shares
1,151,515
2,584,247
Private Acquisition
32.43
Form 4
Robinson, James G. (Independent Director)
Apr-21-2021 - Apr-22-2021
Common Shares
40,000
113,262
Open Market Acquisition
1.14
Form 4
-
Apr-21-2021
Common Shares
2,000
5,685
Open Market Acquisition
-
Form 4
-
Apr-21-2021
Common Shares
6,000
16,974
Open Market Acquisition
-
Form 4
-
Apr-21-2021
Common Shares
4,100
11,599
Open Market Acquisition
-
Form 4
-
Apr-21-2021
Common Shares
900
2,544
Open Market Acquisition
-
Form 4
-
Apr-22-2021
Common Shares
7,000
19,707
Open Market Acquisition
-
Form 4
-
Apr-22-2021
Common Shares
1,900
5,504
Open Market Acquisition
-
Form 4
-
Apr-22-2021
Common Shares
3,100
8,876
Open Market Acquisition
-
Form 4
-
Apr-22-2021
Common Shares
5,000
13,941
Open Market Acquisition
-
Form 4
-
Apr-22-2021
Common Shares
4,949
14,068
Open Market Acquisition
-
Form 4
-
Apr-22-2021
Common Shares
51
144
Open Market Acquisition
-
Form 4
-
Apr-22-2021
Common Shares
800
2,285
Open Market Acquisition
-
Form 4
-
Apr-22-2021
Common Shares
2,900
8,243
Open Market Acquisition
-
Form 4
-
Apr-22-2021
Common Shares
1,100
3,124
Open Market Acquisition
-
Form 4
-
Apr-22-2021
Common Shares
200
567
Open Market Acquisition
-
Form 4
Robinson, James G. (Independent Director)
Jul-10-2019
Common Shares
7,000
16,462
Open Market Acquisition
0.20
Form 4
-
Jul-10-2019
Common Shares
5,834
13,728
Open Market Acquisition
-
Form 4
-
Jul-10-2019
Common Shares
300
706
Open Market Acquisition
-
Form 4
-
Jul-10-2019
Common Shares
600
1,405
Open Market Acquisition
-
Form 4
-
Jul-10-2019
Common Shares
166
390
Open Market Acquisition
-
Form 4
-
Jul-10-2019
Common Shares
100
235
Open Market Acquisition
-
Form 4
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Averback, Paul 
Founder, Chairman, CEO & President
800 936 9669
514 332 2227

Doody, Patrick 
VP, General Counsel & Director
800 936 9669
514 332 2227

Robinson, James G.
Independent Director
800 936 9669
514 332 2227

Morse, David S.
Independent Director
800 936 9669
514 332 2227

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Averback, Paul 
Founder, Chairman, CEO & President
800 936 9669
514 332 2227

Dodd, Lin 
QA and Compliance Manager
800 936 9669
514 332 2227

Doody, Patrick 
VP, General Counsel & Director
800 936 9669
514 332 2227

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
